Asset Details
Do you wish to reserve the book?
UNVEILING AN UNCOMMON COMPLICATION: PLEURAL EFFUSION SECONDARY TO PIOGLITAZONE USE
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
UNVEILING AN UNCOMMON COMPLICATION: PLEURAL EFFUSION SECONDARY TO PIOGLITAZONE USE
Do you wish to request the book?
UNVEILING AN UNCOMMON COMPLICATION: PLEURAL EFFUSION SECONDARY TO PIOGLITAZONE USE
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
UNVEILING AN UNCOMMON COMPLICATION: PLEURAL EFFUSION SECONDARY TO PIOGLITAZONE USE
2025
Overview
Pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, is used in the treatment of type 2 diabetes mellitus by reducing insulin resistance. While peripheral edema and fluid retention are well-documented adverse effects, isolated pleural effusion in the absence of heart failure is rare. We present the fourth reported case of a woman in her 60s with type 2 diabetes who developed recurrent left-sided pleural effusion after the initiation and dose escalation of pioglitazone. The effusion resolved completely following discontinuation of the drug. This case underscores the importance of early recognition of drug-induced pleural effusion and timely cessation of the offending agent to prevent morbidity.
Publisher
Greater Baltimore Medical Center
Subject
